$1.04
7.59% today
Nasdaq, Apr 04, 08:46 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$1.12
-0.65 36.72% 1M
-2.08 65.00% 6M
-0.15 11.81% YTD
-5.74 83.67% 1Y
-20.23 94.75% 3Y
-18.44 94.27% 5Y
-17.08 93.85% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.06 5.08%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $92.93m
Enterprise Value $-141.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.65
EV/Sales (TTM) EV/Sales -4.39
P/S ratio (TTM) P/S ratio 2.88
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth -58.64%
Revenue (TTM) Revenue $32.31m
EBIT (operating result TTM) EBIT $-238.92m
Free Cash Flow (TTM) Free Cash Flow $-219.11m
Cash position $269.91m
EPS (TTM) EPS $-2.88
P/E forward negative
P/S forward 9.77
EV/Sales forward negative
Short interest 20.04%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Editas Medicine, Inc. forecast:

5x Buy
33%
8x Hold
53%
2x Sell
13%

Analyst Opinions

15 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
33%
Hold
53%
Sell
13%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
32 32
59% 59%
100%
- Direct Costs 5.81 5.81
4% 4%
18%
27 27
63% 63%
82%
- Selling and Administrative Expenses 66 66
4% 4%
205%
- Research and Development Expense 193 193
13% 13%
599%
-233 -233
43% 43%
-721%
- Depreciation and Amortization 5.81 5.81
4% 4%
18%
EBIT (Operating Income) EBIT -239 -239
41% 41%
-739%
Net Profit -237 -237
55% 55%
-734%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Neutral
GlobeNewsWire
15 days ago
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J.
Neutral
Seeking Alpha
24 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good morning, everyone. My name is Gena Wang, I'm [Indiscernible] at Biotech An...
Neutral
Seeking Alpha
25 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentified Company Representative Welcome to Leerink Global Healthcare Conference 2025. So this morning, we are, discussing with the Editas Management Team, and we have Erick Lucera, and we have, Gilmore ...
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 246
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today